Novel and Innovative Drug Delivery Systems to Overcome Chemoresistance in Human Malignancies addresses the critical challenge of cancer chemoresistance, synthesizing insights from cancer biology, molecular biology, biotechnology, and nanotechnology. The book explores the complex mechanisms underlying drug resistance, including alterations in key signaling pathways and the tumor microenvironment's role in cancer cell survival. It highlights advancements in drug delivery technologies, such as nanomedicine and biomimetic strategies, which enhance drug targeting and minimize off-target effects. The integration of techniques like CRISPR-Cas9 and artificial intelligence in developing next-generation therapies is also emphasized.
For an academic audience, this book serves as an essential resource to foster interdisciplinary collaboration in cancer research. It equips researchers, clinicians, and industry professionals with the knowledge needed to navigate the evolving landscape of cancer therapeutics, addressing critical challenges in drug delivery and chemoresistance to improve patient outcomes.
1. Title of Book - p. i 2. Cover image - p. i 3. Title page - p. i 4. Table of Contents - p. iii 5. Volume in the bookseries Novel approaches to overcome cancer resistance to conventional therapies - p. ii 6. Copyright - p. iv 7. Aims and Scope of Series “Novel Approaches to Overcome Cancer Resistance to Conventional Therapies” - p. v 8. About the Series Editor - p. vii 9. Aims and Scope of the Volume - p. ix 10. About the Editors - p. xi 11. Preface - p. xiii 12. Contributors - p. xxi 13. Chapter 1. Exploring chemoresistance mechanisms and innovative drug delivery approaches in effective cancer therapy - p. 1 14. Chapter 2. Molecular interplay of hypoxia, aberrant angiogenesis, and immune suppression in cancer chemoresistance - p. 39 15. Chapter 3. Impact of hypoxia, angiogenesis, and immunosuppression in chemoresistance - p. 59 16. Chapter 4. Design and applications of smart biomaterials for anticancer drug delivery systems - p. 77 17. Chapter 5. Revolutionizing precision oncology: Combating chemoresistance with nanorobotics - p. 123 18. Chapter 6. Advanced drug delivery strategies: Nanoparticles, liposomes, dendrimers, and smart biomaterials - p. 145 19. Chapter 7. Epigenetic modulations in cancer chemoresistance: Harnessing nanotechnology for targeted therapy - p. 169 20. Chapter 8. Advancements in cancer immunotherapy: Targeting the tumor immune microenvironment (TIME) - p. 187 21. Chapter 9. Near-infrared responsive photothermal-immunotherapy for overcoming chemoresistance in cancer therapy - p. 203 22. Chapter 10. Combating chemoresistance through RNA-based therapeutic approaches: A mechanistic insight - p. 221 23. Chapter 11. Therapeutic potential of drug repurposing in reversing chemoresistance - p. 255 24. Chapter 12. Ion channels in chemoresistance: A mechanistic overview and CRISPR-based therapeutic strategies - p. 277 25. Chapter 13. CRISPR/Cas9 and gene editing approaches as a solution for chemoresistance - p. 307 26. Chapter 14. Clinical applications and emerging challenges of novel drug delivery systems - p. 327 27. Chapter 15. Exosome and extracellular vesicle-based therapeutics to overcome cancer chemoresistance - p. 349 28. Chapter 16. Preclinical strategies for investigating drug delivery platforms - p. 373 29. Chapter 17. Artificial intelligence and machine learning approaches in rational drug design to overcome cancer chemoresistance - p. 393 30. Chapter 18. Chemoresistance in modern oncology: A multilayered network of signaling, plasticity, and tumor microenvironmental interactions - p. 411 31. Index - p. 423
Novel and Innovative Drug Delivery Systems to Overcome Chemoresistance in Human Malignancies addresses the critical challenge of cancer chemoresistance, synthesizing insights from cancer biology, molecular biology, biotechnology, and nanotechnology. The book explores the complex mechanisms underlying drug resistance, including alterations in key signaling pathways and the tumor microenvironment's role in cancer cell survival. It highlights advancements in drug delivery technologies, such as nanomedicine and biomimetic strategies, which enhance drug targeting and minimize off-target effects. The integration of techniques like CRISPR-Cas9 and artificial intelligence in developing next-generation therapies is also emphasized.
For an academic audience, this book serves as an essential resource to foster interdisciplinary collaboration in cancer research. It equips researchers, clinicians, and industry professionals with the knowledge needed to navigate the evolving landscape of cancer therapeutics, addressing critical challenges in drug delivery and chemoresistance to improve patient outcomes.
1. Title of Book - p. i 2. Cover image - p. i 3. Title page - p. i 4. Table of Contents - p. iii 5. Volume in the bookseries Novel approaches to overcome cancer resistance to conventional therapies - p. ii 6. Copyright - p. iv 7. Aims and Scope of Series “Novel Approaches to Overcome Cancer Resistance to Conventional Therapies” - p. v 8. About the Series Editor - p. vii 9. Aims and Scope of the Volume - p. ix 10. About the Editors - p. xi 11. Preface - p. xiii 12. Contributors - p. xxi 13. Chapter 1. Exploring chemoresistance mechanisms and innovative drug delivery approaches in effective cancer therapy - p. 1 14. Chapter 2. Molecular interplay of hypoxia, aberrant angiogenesis, and immune suppression in cancer chemoresistance - p. 39 15. Chapter 3. Impact of hypoxia, angiogenesis, and immunosuppression in chemoresistance - p. 59 16. Chapter 4. Design and applications of smart biomaterials for anticancer drug delivery systems - p. 77 17. Chapter 5. Revolutionizing precision oncology: Combating chemoresistance with nanorobotics - p. 123 18. Chapter 6. Advanced drug delivery strategies: Nanoparticles, liposomes, dendrimers, and smart biomaterials - p. 145 19. Chapter 7. Epigenetic modulations in cancer chemoresistance: Harnessing nanotechnology for targeted therapy - p. 169 20. Chapter 8. Advancements in cancer immunotherapy: Targeting the tumor immune microenvironment (TIME) - p. 187 21. Chapter 9. Near-infrared responsive photothermal-immunotherapy for overcoming chemoresistance in cancer therapy - p. 203 22. Chapter 10. Combating chemoresistance through RNA-based therapeutic approaches: A mechanistic insight - p. 221 23. Chapter 11. Therapeutic potential of drug repurposing in reversing chemoresistance - p. 255 24. Chapter 12. Ion channels in chemoresistance: A mechanistic overview and CRISPR-based therapeutic strategies - p. 277 25. Chapter 13. CRISPR/Cas9 and gene editing approaches as a solution for chemoresistance - p. 307 26. Chapter 14. Clinical applications and emerging challenges of novel drug delivery systems - p. 327 27. Chapter 15. Exosome and extracellular vesicle-based therapeutics to overcome cancer chemoresistance - p. 349 28. Chapter 16. Preclinical strategies for investigating drug delivery platforms - p. 373 29. Chapter 17. Artificial intelligence and machine learning approaches in rational drug design to overcome cancer chemoresistance - p. 393 30. Chapter 18. Chemoresistance in modern oncology: A multilayered network of signaling, plasticity, and tumor microenvironmental interactions - p. 411 31. Index - p. 423
